Dan V. Iosifescu, MD

Rapidity of Improvement With Intranasal Esketamine for MDD

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.

Maurizio Fava, Manish K. Jha, George I. Papakostas, et al

Original Research

Effect of Benzodiazepines on Antidepressant Effects of Ketamine

November 14, 2022

Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...

Maurizio Fava, Madhukar H. Trivedi, Manish K. Jha, et al

Original Research

Very Low-Level Transcranial Photobiomodulation for MDD

August 8, 2022

Transcranial photobiomodulation may be efficacious for major depressive disorder, but the optimal dose is not known. Here, a very low dose was studied to establish a threshold for lack...

Albert Yeung, David Mischoulon, David Schoenfeld, et al

Original Research

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD

May 30, 2022

Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...

Maurizio Fava, Dan V. Iosifescu, Amanda Jones, et al

ASCP Corner

Wrestling With Antidepressant Use in Bipolar Disorder

January 19, 2021

The question of whether, and when, antidepressants are appropriate in bipolar disorder is a hotly debated topic. This ASCP Corner article summarizes the key concepts with greatest relevance for...

Andrew A. Nierenberg, Joseph F. Goldberg, Dan V. Iosifescu

Meta-Analysis

Esketamine Augmentation in Major Depressive Disorder

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...

Maurizio Fava, Manish K. Jha, George I. Papakostas, et al

Commentary

Maintaining the Initial Clinical Response After Ketamine in Bipolar and Unipolar Depression: An Important Next-Step Challenge

June 24, 2015

Dan V. Iosifescu

Original Research

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

September 2, 2014

James W. Murrough, Andrew M. Perez, Sanjay J. Mathew, et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

July 15, 2013

Maurizio Fava, Andrew A. Nierenberg, Roy H. Perlis, et al

Original Research

Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression: A Report From the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) Trial

January 15, 2013

Madhukar H. Trivedi, Sidney Zisook, Andrew F. Leuchter, et al

Original Research

A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression

November 2, 2010

David Mischoulon, Maurizio Fava, Dan V. Iosifescu, et al

Original Research

A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment

November 15, 2006

Maurizio Fava, George I. Papakostas, Franco Benazzi, et al

Rapidity of Improvement With Intranasal Esketamine for MDD

Effect of Benzodiazepines on Antidepressant Effects of Ketamine

Very Low-Level Transcranial Photobiomodulation for MDD

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD

Wrestling With Antidepressant Use in Bipolar Disorder

Esketamine Augmentation in Major Depressive Disorder

Maintaining the Initial Clinical Response After Ketamine in Bipolar and Unipolar Depression: An Important Next-Step Challenge

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression: A Report From the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) Trial

A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression

A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment

ELSEWHERE:

FOLLOW US:

Dan V. Iosifescu, MD

Rapidity of Improvement With Intranasal Esketamine for MDD

Effect of Benzodiazepines on Antidepressant Effects of Ketamine

Very Low-Level Transcranial Photobiomodulation for MDD

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD

Wrestling With Antidepressant Use in Bipolar Disorder

Esketamine Augmentation in Major Depressive Disorder

Maintaining the Initial Clinical Response After Ketamine in Bipolar and Unipolar Depression: An Important Next-Step Challenge

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression: A Report From the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) Trial

A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression

A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles